Chronic Dermatophytosis: Clinico-Mycological Determinants and Antifungal Susceptibility Pattern

Overview

Journal Indian J Dermatol

Specialty Dermatology

Date 2021 Aug 27

PMID 34446965

Authors

S Sooriya

Sabeena Jayapalan

G Mini

S Manjusree

Lakshmy Nandakumar

Affiliations

Soon will be listed here.

Abstract

Background: Recent years have witnessed a dramatic increase in chronic unresponsive dermatophytosis. A study was conducted to quantify the proportion of patients with chronic dermatophytosis and to determine the clinico-mycological predictors of chronicity including antifungal susceptibility.

Methods: Hospital-based cross-sectional study design was adopted. Four hundred and twenty-five patients were studied. The outcome variable was chronic dermatophytosis and the determinants were clinico-mycological characteristics. Chi-square and odds ratio (OR) with 95% confidence interval (CI) were calculated.

Results: Chronic dermatophytosis was seen in 29.4%. Past history of dermatophytosis, OR 0.44 (95% CI 0.28-0.68); family history of dermatophytosis, OR 1.66 (95% CI 1.06-2.56); HIV infection, OR 9.88 (95% CI 1.09-89.33); treatment with topical antifungals, OR 2.4 (95% CI 1.5-3.9); systemic antifungals, OR 3.9 (95% CI 2.5-6.1); topical steroids, OR 2.02 (95% CI 1.25-3.25); multiple-site infection, OR 1.97 (95% CI 1.24-3.13); and tinea unguium, OR 6.52 (95% CI 2.89-14.7) were the significant determinants. (73.6%) was the most common isolate followed by and (13.2%) each. A percentage of 77.4 of the isolates were resistant-73.6% isolates to terbinafine and 3.8% isolates to fluconazole. None of the isolates were resistant to itraconazole.

Conclusion: Significant determinants were host-related factors. Thorough history taking, patient examination, and education can improve the present scenario. Microbiological resistance was not a significant predictor. High proportion of resistant strains should be an eye opener. Developing and adopting a standard uniform treatment protocol throughout the country should be the need of the hour.

References

Azambuja C, Pimmel L, Baracy Klafke G, Xavier M . Onychomycosis: clinical, mycological and in vitro susceptibility testing of isolates of Trichophyton rubrum. An Bras Dermatol. 2014; 89(4):581-6. PMC: 4148271. DOI: 10.1590/abd1806-4841.20142630. View

Bindu V, Pavithran K . Clinico-mycological study of dermatophytosis in Calicut. Indian J Dermatol Venereol Leprol. 2007; 68(5):259-61. View

Singh S, Shukla P . End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients. Indian J Dermatol Venereol Leprol. 2018; 84(5):554-557. DOI: 10.4103/ijdvl.IJDVL_526_17. View

Bishnoi A, Vinay K, Dogra S . Emergence of recalcitrant dermatophytosis in India. Lancet Infect Dis. 2018; 18(3):250-251. DOI: 10.1016/S1473-3099(18)30079-3. View

Das S, De A, Saha R, Sharma N, Khemka M, Singh S . The Current Indian Epidemic of Dermatophytosis: A Study on Causative Agents and Sensitivity Patterns. Indian J Dermatol. 2020; 65(2):118-122. PMC: 7059464. DOI: 10.4103/ijd.IJD_203_19. View

Sharma R, Adhikari L, Sharma R . Recurrent dermatophytosis: A rising problem in Sikkim, a Himalayan state of India. Indian J Pathol Microbiol. 2018; 60(4):541-545. DOI: 10.4103/IJPM.IJPM_831_16. View

Panda S, Verma S . The menace of dermatophytosis in India: The evidence that we need. Indian J Dermatol Venereol Leprol. 2017; 83(3):281-284. DOI: 10.4103/ijdvl.IJDVL_224_17. View

Fernandez-Torres B, Carrillo A, Martin E, Del Palacio A, Moore M, Valverde A . In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother. 2001; 45(9):2524-8. PMC: 90687. DOI: 10.1128/AAC.45.9.2524-2528.2001. View

Mahajan S, Tilak R, Kaushal S, Mishra R, Pandey S . Clinico-mycological study of dermatophytic infections and their sensitivity to antifungal drugs in a tertiary care center. Indian J Dermatol Venereol Leprol. 2017; 83(4):436-440. DOI: 10.4103/ijdvl.IJDVL_519_16. View

10.

Noronha T, Tophakhane R, Nadiger S . Clinico-microbiological study of dermatophytosis in a tertiary-care hospital in North Karnataka. Indian Dermatol Online J. 2016; 7(4):264-71. PMC: 4976403. DOI: 10.4103/2229-5178.185488. View

11.

Agarwalla A, Jacob M, Sethi M, Parija S, Singh N . A clinico-mycological study of dermatophytoses in Nepal. J Dermatol. 2001; 28(1):16-21. DOI: 10.1111/j.1346-8138.2001.tb00080.x. View

12.

Sardana K, Kaur R, Arora P, Goyal R, Ghunawat S . Is Antifungal Resistance a Cause for Treatment Failure in Dermatophytosis: A Study Focused on Tinea Corporis and Cruris from a Tertiary Centre?. Indian Dermatol Online J. 2018; 9(2):90-95. PMC: 5885633. DOI: 10.4103/idoj.IDOJ_137_17. View

13.

Dogra S, Uprety S . The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive?. Indian Dermatol Online J. 2016; 7(2):73-6. PMC: 4804598. DOI: 10.4103/2229-5178.178100. View

14.

Bhatia V, Sharma P . Determination of minimum inhibitory concentrations of itraconazole, terbinafine and ketoconazole against dermatophyte species by broth microdilution method. Indian J Med Microbiol. 2015; 33(4):533-7. DOI: 10.4103/0255-0857.167341. View

15.

Bhatia V, Sharma P . Epidemiological studies on Dermatophytosis in human patients in Himachal Pradesh, India. Springerplus. 2015; 3:134. PMC: 4320242. DOI: 10.1186/2193-1801-3-134. View

16.

Nenoff P, Verma S, Vasani R, Burmester A, Hipler U, Wittig F . The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes-A molecular study. Mycoses. 2018; 62(4):336-356. DOI: 10.1111/myc.12878. View

17.

Hogl F, RAAB W . [The influence of steroids on the antifungal and antibacterial activities of imidazole derivatives (author's transl)]. Mykosen. 1980; 23(8):426-39. View

18.

Verma S, Madhu R . The Great Indian Epidemic of Superficial Dermatophytosis: An Appraisal. Indian J Dermatol. 2017; 62(3):227-236. PMC: 5448256. DOI: 10.4103/ijd.IJD_206_17. View

19.

Vineetha M, Sheeja S, Celine M, Sadeep M, Palackal S, Shanimole P . Profile of Dermatophytosis in a Tertiary Care Center. Indian J Dermatol. 2018; 63(6):490-495. PMC: 6233031. DOI: 10.4103/ijd.IJD_177_18. View

20.

Asticcioli S, Di Silverio A, Sacco L, Fusi I, Vincenti L, Romero E . Dermatophyte infections in patients attending a tertiary care hospital in northern Italy. New Microbiol. 2009; 31(4):543-8. View